Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2021-03-02 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
2021年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2021 first extraordinary general meeting (临时股东大会) of Shenzhen BGI Genomics Co., Ltd. It includes information about the meeting date, attendance, voting results on multiple proposals, and legal opinions confirming the validity of the meeting and resolutions. The content focuses on the official voting results of shareholder decisions at a general meeting. There is no indication that this is a full annual report, interim report, or earnings release. The document is not a proxy solicitation or a management report but specifically reports the voting outcomes of the shareholder meeting. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 4417 characters, which is sufficient to contain detailed voting results rather than a brief announcement or a report publication notice.
2021-03-02 Chinese
国浩律师（深圳）事务所关于深圳华大基因股份有限公司二〇二一年第一次临时股东大会之法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening and procedures of the 2021 first extraordinary general meeting (临时股东大会) of Shenzhen BGI Genomics Co., Ltd. It details the legality of the meeting's convening, attendance, voting procedures, and results. The document does not contain financial statements or performance data but focuses on the legal compliance and validity of the shareholder meeting and its resolutions. This type of document is typically associated with announcements or confirmations of shareholder meeting results or related legal opinions, not the meeting materials themselves or the full voting results announcement. Given the detailed voting results and legal opinion on the meeting, it aligns best with Declaration of Voting Results & Voting Rights Announcements (DVA). The document length and content indicate it is not a brief announcement but a formal legal opinion on the meeting and voting results, supporting classification as DVA rather than a simple announcement or regulatory filing.
2021-03-02 Chinese
2020年度业绩快报
Earnings Release Classification · 95% confidence The document is titled as a "2020年度业绩快报" which translates to "2020 Annual Performance Express Report" or "2020 Annual Earnings Quick Report." It contains preliminary financial data for the year 2020, including revenue, profit, net income, earnings per share, and asset information. The document explicitly states that the data is preliminary, unaudited, and subject to change upon final audit in the annual report. It also mentions that the final audited data will be disclosed in the 2020 Annual Report. The document is relatively short (2430 characters) and serves as an initial earnings announcement rather than a full comprehensive annual report. This matches the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. It is not the full Annual Report (10-K), nor is it an announcement of the report publication (RPA). Therefore, the correct classification is Earnings Release (ER). FY 2020
2021-02-26 Chinese
关于召开2021年第一次临时股东大会的提示性公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement about the convening of the 2021 first extraordinary general meeting (临时股东大会) of Shenzhen BGI Genomics Co., Ltd. It includes information about the meeting date, voting procedures (both onsite and online), agenda items to be discussed and voted on, registration details, and attachments such as proxy forms and voting instructions. There is no financial data, earnings information, or management discussion of financial results. The document is not a report itself but an announcement and notice related to a shareholders' meeting. It does not contain voting results or changes in management but is a notice to shareholders about the meeting and how to participate. Therefore, it fits best into the category of a regulatory announcement related to shareholder meetings but not the voting results or the meeting materials themselves. Given the specificity of the content, it is best classified as a Regulatory Filing (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2021-02-25 Chinese
关于控股子公司十五项产品取得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement from Shenzhen BGI Genomics Co., Ltd. regarding its controlling subsidiary obtaining medical device registration certificates for fifteen products. The content focuses on product registration details, market situation, and potential impact on the company. There is no financial data, no mention of financial results, no regulatory certifications or attestations, no meeting materials, no voting results, no management changes, no legal proceedings, no capital or financing updates, and no merger or acquisition information. The document is relatively short (3434 characters) and is an announcement of a regulatory approval event related to product registration. This fits best under a general regulatory announcement category rather than a financial report or other specific filing type. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2021-02-18 Chinese
关于持股5%以上股东减持股份计划的预披露公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement regarding a plan by a shareholder holding more than 5% of the company's shares to reduce their holdings. It details the shareholder's identity, shareholding percentage, planned reduction amount, methods, timing, and legal compliance. The content focuses on shareholding changes and reduction plans by a major shareholder, which aligns with the category of Major Shareholding Notification. The document is not a financial report, earnings release, or management report, nor is it an announcement of a report publication. It is a regulatory announcement about shareholding changes by a significant shareholder.
2021-02-10 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.